NO305581B1 - Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose - Google Patents

Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose

Info

Publication number
NO305581B1
NO305581B1 NO933044A NO933044A NO305581B1 NO 305581 B1 NO305581 B1 NO 305581B1 NO 933044 A NO933044 A NO 933044A NO 933044 A NO933044 A NO 933044A NO 305581 B1 NO305581 B1 NO 305581B1
Authority
NO
Norway
Prior art keywords
treatment
osteoporosis
hormone
combination
dosage form
Prior art date
Application number
NO933044A
Other languages
English (en)
Norwegian (no)
Other versions
NO933044L (no
NO933044D0 (no
Inventor
Jocelyn Elaine Mcosker
Original Assignee
Procter & Gamble Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble Pharma filed Critical Procter & Gamble Pharma
Publication of NO933044L publication Critical patent/NO933044L/no
Publication of NO933044D0 publication Critical patent/NO933044D0/no
Publication of NO305581B1 publication Critical patent/NO305581B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Removal Of Specific Substances (AREA)
NO933044A 1991-02-26 1993-08-26 Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose NO305581B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66177791A 1991-02-26 1991-02-26
PCT/US1992/000854 WO1992014474A1 (en) 1991-02-26 1992-01-31 Methods for the treatment of osteoporosis

Publications (3)

Publication Number Publication Date
NO933044L NO933044L (no) 1993-08-26
NO933044D0 NO933044D0 (no) 1993-08-26
NO305581B1 true NO305581B1 (no) 1999-06-28

Family

ID=24655074

Family Applications (1)

Application Number Title Priority Date Filing Date
NO933044A NO305581B1 (no) 1991-02-26 1993-08-26 Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose

Country Status (18)

Country Link
US (1) US6329354B1 (de)
EP (1) EP0573604B1 (de)
JP (1) JP3727332B2 (de)
KR (1) KR100240358B1 (de)
AT (1) ATE119777T1 (de)
AU (1) AU664368B2 (de)
CA (1) CA2101275C (de)
CZ (1) CZ282609B6 (de)
DE (1) DE69201725T2 (de)
DK (1) DK0573604T3 (de)
ES (1) ES2069424T3 (de)
HU (1) HU215124B (de)
IE (1) IE65963B1 (de)
NO (1) NO305581B1 (de)
NZ (1) NZ241717A (de)
RU (1) RU2113848C1 (de)
SK (1) SK90093A3 (de)
WO (1) WO1992014474A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2119337C1 (ru) * 1992-03-21 1998-09-27 Энтек Гезельшафт фюр Эндокринологише Технологи мбХ Трансдермальный препарат продленного действия с антиостеопоротической активностью
JPH08502287A (ja) * 1992-10-09 1996-03-12 ジ・アップジョン・カンパニー 抗炎症剤としてのピリミジンビスホスホン酸エステルおよび（アルコキシメチルホスフィニル）アルキルホスホン酸
US6399592B1 (en) 1992-12-23 2002-06-04 Merck & Co., Inc. Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
AU5953894A (en) * 1992-12-23 1994-07-19 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss
EP0697890A1 (de) * 1993-05-15 1996-02-28 Roche Diagnostics GmbH Tablette mit verbesserter bioverfügbarkeit enthaltend dichlormethylendiphosphonsäure als wirkstoff
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
ES2262145T3 (es) * 1994-12-28 2006-11-16 Gador S.A. Composicion anabolica para la masa osea que comprende olpadronato.
DE19635883A1 (de) * 1996-09-04 1998-03-05 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einer Östriol enthaltenden Wirkstoffkombination
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
EP0949928A4 (de) * 1996-11-25 2000-09-13 Merck & Co Inc Zusammen verabreichte androgene und diphosphonverbindungen zur behandlung von krankheiten
US6692763B1 (en) * 1998-11-19 2004-02-17 The Regents Of The University Of California Methods for treating postmenopausal women using ultra-low doses of estrogen
AR013994A1 (es) * 1998-10-30 2001-01-31 Gador Sa Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.
CN1217666C (zh) * 1998-12-25 2005-09-07 东丽株式会社 白介素－6产生抑制剂
US6339078B1 (en) 1999-07-20 2002-01-15 University Of Florida Research Foundation, Inc. Methods of prevention and treatment of ischemic damage
US6326365B1 (en) 1999-07-20 2001-12-04 Apollo Biopharmaceutics, Inc. Methods of prevention and treatment of ischemic damage
US7335650B2 (en) 2000-01-14 2008-02-26 Sterix Limited Composition
US6653298B2 (en) 2000-01-14 2003-11-25 Sterix Limited Composition
US20040038946A1 (en) * 2001-04-27 2004-02-26 Wilson Lon J. Fullerene-based drugs targeted to bone
WO2009068567A1 (en) * 2007-11-30 2009-06-04 Novartis Ag C2-c5-alkyl-imidazole-bisphosphonates
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
JP5852569B2 (ja) 2009-07-31 2016-02-03 タール ファーマシューティカルズ，インコーポレイテッド 結晶化方法および生物学的利用能
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3553314A (en) 1968-12-23 1971-01-05 Procter & Gamble Oral compositions for calculus retardation
US3683080A (en) 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
EP0088462A3 (de) * 1982-03-01 1984-06-06 The Procter & Gamble Company Entzündungshemmende und antirheumatische Zusammensetzung mit Gehalt an einem Organophosphonat und einem Steroiden
EP0381296B1 (de) * 1984-04-30 1994-11-30 THE PROCTER & GAMBLE COMPANY Ausrüstung für die Verwendung bei der Behandlung von Osteoporose
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
IL86951A (en) 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
NO933044L (no) 1993-08-26
DE69201725T2 (de) 1996-04-18
JP3727332B2 (ja) 2005-12-14
NZ241717A (en) 1997-02-24
ES2069424T3 (es) 1995-05-01
RU2113848C1 (ru) 1998-06-27
HU215124B (hu) 1998-09-28
CZ282609B6 (cs) 1997-08-13
DE69201725D1 (de) 1995-04-20
JPH06505501A (ja) 1994-06-23
HU9302407D0 (en) 1993-11-29
CA2101275A1 (en) 1992-08-27
DK0573604T3 (da) 1995-05-29
KR100240358B1 (ko) 2000-02-01
ATE119777T1 (de) 1995-04-15
AU664368B2 (en) 1995-11-16
WO1992014474A1 (en) 1992-09-03
EP0573604B1 (de) 1995-03-15
NO933044D0 (no) 1993-08-26
SK90093A3 (en) 1994-09-07
CA2101275C (en) 1998-08-04
EP0573604A1 (de) 1993-12-15
AU1643392A (en) 1992-09-15
US6329354B1 (en) 2001-12-11
IE65963B1 (en) 1995-11-29
CZ175593A3 (en) 1994-04-13
HUT66429A (en) 1994-11-28
IE920584A1 (en) 1992-08-26

Similar Documents

Publication Publication Date Title
NO305581B1 (no) Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose
CA2285203A1 (en) Compositions containing capsaicin or capsaicin analogues and a local anesthetic
RU93054017A (ru) Способ лечения остеопороза, композиция для лечения остеопороза, применение активно действующего на кости фосфоната и эстрогенного гормона для лечения остеопороза
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ES2055911T3 (es) Compuesto farmaceutico adelgazante.
RU94046316A (ru) Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза
PT946151E (pt) Forma de dosagem de dose crescente
DE69634357D1 (de) Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten
ATE218350T1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ES2114851T3 (es) Utilizacion de composiciones de liberacion sostenida que contienen gnrh, lhrh o derivados de las mismas.
DE69316013D1 (de) Verwendung von phosphinate zur behandlung der osteoporose
DE69420776D1 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
ATE88633T1 (de) Verwendung von bestimmten calcium-citrate-malaten zur herstellung einer pharmazeutischen zubereitung fuer die behandlung von osteoporose.
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE60120371D1 (de) Verwendung von wachstumshormon in niederen dosen